Managing Discovery in the Life Sciences
Harnessing Creativity to Drive Biomedical Innovation

Addresses in roughly equal measure the science and management behind several recent marketable biomedical innovations.

Philip A. Rea (Author), Mark V. Pauly (Author), Lawton R. Burns (Author)

9781107130906, Cambridge University Press

Hardback, published 1 February 2018

554 pages, 5 b/w illus. 39 colour illus. 3 tables
23.5 x 15.8 x 2.9 cm, 1.01 kg

'This new study by Philip A. Rea, Mark V. Pauly, and Lawton R. Burns provides useful information and insightful analyses of the biomedical innovation process.' Henry Grabowski, Professor Emeritus of Economics, Duke University, North Carolina

In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.

Preface
1. Discoveries now and then: shifting incentives and expectations Mark V. Pauly, Philip A. Rea and Lawton R. Burns
2. Pharma trends: not what they seem Kyle Myers and Mark V. Pauly
3. Profit maximizing drug firms: models and myths Vicki Chen and Mark V. Pauly
Transitional note: introduction to the case studies
4. The Statins: cholesterols 'penicillins' Philip A. Rea
5. ACE inhibitors: kidney clamps, snake venoms and peptidomimetics Alec Ren and Philip A. Rea
6. Angioplasty: catheters, guidewires and balloons Simon Basseyn, Sourav Bose, Lawton R. Burns and Chris Groskaufmanis
7. Hepatitis C: when cures and prices go viral Stephen Goldstein, Peter M. Stokes, Connie Lu and Philip A. Rea
8. Alzheimer's: America's new most feared disease Julian Pei, John Q. Trojanowski, Peter M. Stokes, Katherine Clark, Mark V. Pauly and Philip A. Rea
9. Metformin: to the brink and back Anderson Y. Tien and Philip A Rea
10. Medical genomics: personalized precision Marc S. Williams
11. Gleevec: from broken chromosomes to precision cancer therapy Vivek Nimgaonkar and Philip A. Rea
12. Regeneron: agility, resilience and balance Lawton R. Burns, Alex Rosen, Steven Nichtberger and Philip A. Rea
13. Avastin and Lucentis: both for eyesight in hindsight Osama Ahmed, Mark V. Pauly, Peter M. Stokes and Philip A. Rea
14. CAR T-cell therapy: cures for ALL and more? Stephen Goldstein, Amy Le and Philip A. Rea
15. Organizing discovery: wild ducks nested in multilevel ecosystems Lawton R. Burns and Philip A. Rea
16. Can government help with the creatively unexpected? Mark V. Pauly, Lawton R. Burns and Philip A. Rea
Appendix: three key elements in the discovery process: historical and philosophical antecedents Mark V. Pauly
Index.

Subject Areas: Science funding & policy [PDK], Industrial applications of scientific research & technological innovation [PDG], Pharmacology [MMG], Business innovation [KJD], Health economics [KCQ], Economics [KC]